Eso-Sponge® for anastomotic leakage after oesophageal resection or perforation: outcomes from a national, prospective multicentre registry.


Journal

BJS open
ISSN: 2474-9842
Titre abrégé: BJS Open
Pays: England
ID NLM: 101722685

Informations de publication

Date de publication:
08 03 2022
Historique:
received: 06 12 2021
revised: 27 01 2022
accepted: 13 02 2022
entrez: 22 4 2022
pubmed: 23 4 2022
medline: 26 4 2022
Statut: ppublish

Résumé

Anastomotic leakage (AL) after oesophagectomy and oesophageal perforations are associated with significant morbidity and mortality. Minimally invasive endoscopy is often used as first-line treatment, particularly endoluminal vacuum therapy (EVT). The aim was to assess the performance of the first commercially available endoluminal vacuum device (Eso-Sponge®) in the management of AL and perforation of the upper gastrointestinal tract (GIT). The Eso-Sponge® registry was designed in 2014 as a prospective, observational, national, multicentre registry. Patients were recruited with either AL or perforation within the upper GIT. Data were collected with a standardized form and transferred into a web-based platform. Twenty hospitals were enrolled at the beginning of the study (registration number NCT02662777; http://www.clinicaltrials.gov). The primary endpoint was successful closure of the oesophageal defect. Eleven out of 20 centres recruited patients. A total of 102 patients were included in this interim analysis; 69 patients with AL and 33 with a perforation were treated by EVT. In the AL group, a closure of 91 per cent was observed and 76 per cent was observed in the perforation group. The occurrence of mediastinitis (P = 0.002) and the location of the defect (P = 0.008) were identified as significant predictors of defect closure. The Eso-Sponge® registry offers the opportunity to collate data on EVT with a uniform, commercially available product to improve standardization. Our data show that EVT with the Eso-Sponge® is an option for the management of AL and perforation within the upper GIT.

Sections du résumé

BACKGROUND
Anastomotic leakage (AL) after oesophagectomy and oesophageal perforations are associated with significant morbidity and mortality. Minimally invasive endoscopy is often used as first-line treatment, particularly endoluminal vacuum therapy (EVT). The aim was to assess the performance of the first commercially available endoluminal vacuum device (Eso-Sponge®) in the management of AL and perforation of the upper gastrointestinal tract (GIT).
METHODS
The Eso-Sponge® registry was designed in 2014 as a prospective, observational, national, multicentre registry. Patients were recruited with either AL or perforation within the upper GIT. Data were collected with a standardized form and transferred into a web-based platform. Twenty hospitals were enrolled at the beginning of the study (registration number NCT02662777; http://www.clinicaltrials.gov). The primary endpoint was successful closure of the oesophageal defect.
RESULTS
Eleven out of 20 centres recruited patients. A total of 102 patients were included in this interim analysis; 69 patients with AL and 33 with a perforation were treated by EVT. In the AL group, a closure of 91 per cent was observed and 76 per cent was observed in the perforation group. The occurrence of mediastinitis (P = 0.002) and the location of the defect (P = 0.008) were identified as significant predictors of defect closure.
CONCLUSIONS
The Eso-Sponge® registry offers the opportunity to collate data on EVT with a uniform, commercially available product to improve standardization. Our data show that EVT with the Eso-Sponge® is an option for the management of AL and perforation within the upper GIT.

Identifiants

pubmed: 35451010
pii: 6572150
doi: 10.1093/bjsopen/zrac030
pmc: PMC9023777
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02662777']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd.

Références

Kongressbd Dtsch Ges Chir Kongr. 2001;118:278-81
pubmed: 11824262
BMC Surg. 2019 Apr 11;19(1):37
pubmed: 30975210
Hepatogastroenterology. 2001 Sep-Oct;48(41):1517-20
pubmed: 11677999
Endosc Int Open. 2015 Dec;3(6):E554-8
pubmed: 26716111
Chirurg. 2014 Dec;85(12):1081-93
pubmed: 24920346
Ann Thorac Surg. 2004 Apr;77(4):1475-83
pubmed: 15063302
Eur J Surg Oncol. 2000 Mar;26(2):168-71
pubmed: 10744938
Endoscopy. 2013 Jun;45(6):433-8
pubmed: 23733727
Surg Endosc. 2009 Oct;23(10):2258-62
pubmed: 19184216
Chirurg. 2008 Jan;79(1):30-7
pubmed: 18066508
Surg Endosc. 2017 Sep;31(9):3449-3458
pubmed: 28078463
J Visc Surg. 2010 Jun;147(3):e117-28
pubmed: 20833121
Endoscopy. 2010 Jul;42(7):599-602
pubmed: 20432210
Ann Thorac Surg. 2014 Mar;97(3):1029-35
pubmed: 24444874
Chirurg. 2019 Jan;90(Suppl 1):1-6
pubmed: 30456644
Surg Endosc. 2013 Oct;27(10):3883-90
pubmed: 23708716
Surg Endosc. 2017 Jun;31(6):2687-2696
pubmed: 27709328
Gastrointest Endosc. 2010 Feb;71(2):382-6
pubmed: 19879566
Surg Endosc. 2018 Apr;32(4):1906-1914
pubmed: 29218673
J Thorac Cardiovasc Surg. 2005 Feb;129(2):254-60
pubmed: 15678033
Gastroenterol Res Pract. 2018 Apr 04;2018:1697968
pubmed: 29849581
Endoscopy. 2010 Sep;42(9):693-8
pubmed: 20806153
Lancet. 2013 Feb 2;381(9864):400-12
pubmed: 23374478
Dis Esophagus. 2009;22(4):374-80
pubmed: 19207557
Surg Endosc. 2014 Mar;28(3):896-901
pubmed: 24149851
Langenbecks Arch Surg. 2016 May;401(3):323-31
pubmed: 27020672
Endoscopy. 2014 Aug;46(8):693-711
pubmed: 25046348
Dig Endosc. 2021 Sep;33(6):892-902
pubmed: 33300634
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e513-9
pubmed: 22014951
Endoscopy. 2011;43 Suppl 2 UCTN:E64-5
pubmed: 21341185
N Engl J Med. 1993 Oct 28;329(18):1302-7
pubmed: 7692297
Dis Esophagus. 2010 Apr;23(3):185-90
pubmed: 19863642
Endoscopy. 2010 Jul;42(7):595-8
pubmed: 20593338
J Gastrointest Surg. 2012 Nov;16(11):2145-50
pubmed: 22948839
J Gastrointest Surg. 2016 Feb;20(2):237-43
pubmed: 26643296
Ann Thorac Surg. 2008 Feb;85(2):S751-6
pubmed: 18222210
Surgery. 2010 Mar;147(3):339-51
pubmed: 20004450
Eur J Cardiothorac Surg. 2005 Feb;27(2):337-43
pubmed: 15691693
World J Gastroenterol. 2014 Jun 28;20(24):7767-76
pubmed: 24976714

Auteurs

Florian Richter (F)

Department of General, Visceral-, Thoracic-, Transplantation- and Paediatric Surgery, University Medical Center Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.

Alexander Hendricks (A)

Department of General Surgery, University Hospital Rostock, Rostock, Germany.

Bodo Schniewind (B)

Department of General Surgery and Thoracic Surgery, Hospital of Lueneburg, Lueneburg, Germany.

Jochen Hampe (J)

Medical Department I, University Hospital Dresden, TU Dresden, Dresden, Germany.

Nils Heits (N)

Department of General, Visceral-, Thoracic-, Transplantation- and Paediatric Surgery, University Medical Center Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.

Witigo von Schönfels (W)

Department of General, Visceral-, Thoracic-, Transplantation- and Paediatric Surgery, University Medical Center Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.

Benedikt Reichert (B)

Department of General, Visceral-, Thoracic-, Transplantation- and Paediatric Surgery, University Medical Center Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.

Katrin Eberle (K)

Department of Internal Medicine, Gastroenterology, Sophien-u. Hufeland Hospital, Weimar, Germany.

Mark Ellrichmann (M)

Department of Internal Medicine I, University Medical Centre Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.

Petra Baumann (P)

Aesculap AG, Medical Scientific Affairs, Tuttlingen, Germany.

Jan-Hendrik Egberts (JH)

Department of Surgery, Israelitisches Krankenhaus, Hamburg, Germany.

Thomas Becker (T)

Department of General, Visceral-, Thoracic-, Transplantation- and Paediatric Surgery, University Medical Center Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.

Clemens Schafmayer (C)

Department of General Surgery, University Hospital Rostock, Rostock, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH